Imperial shrugs off Myblu denial in US with next gen expansion elsewhere

Expanding sales of Imperial Brands’ next generation products into new markets has more than compensated the company for the effect of the US Food and Drug Administration (FDA)’s marketing denial order (MDO) for its Myblu vaping product.

The company said new markets for vapour, heated tobacco and modern oral products which it groups together as its next generation product (NGP) segment brought in more than enough new revenue to offset the loss of Myblu from the US market.

Read full article
I'm already a subscriber

Antonia Di Lorenzo

Assistant news editor
Antonia is a member of the editorial team and holds a masters degree in Law from the University of Naples Federico II, Italy. She moved in 2013 to London, where she completed a postgraduate course at the London School of Journalism. In the UK, she worked as a news reporter for a financial newswire and a magazine before moving to Barcelona in 2019.

Our Key Benefits

The global e-cigarette market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

ECigIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization